New lipid-modifying therapies

Expert Opinion on Investigational Drugs

Volumn 12, Issue 3, 2003, Pages 325-335

  Bruckert, Eric ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cardiovascular disease; Cholesterol absorption; Combination therapy; Low density lipoprotein; Statin

Indexed keywords

1,4 BIS[[1 CYCLOHEXYL 3 (4 DIMETHYLAMINOPHENYL)UREIDO]METHYL]CYCLOHEXANE; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; BMS 201038; BMS 212122; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CJ 15 183; CJ 15183; COLESEVELAM; ER 27856; ER 28448; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOPROTEINASE INHIBITOR; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROTEIN INHIBITOR; RESIN; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 53601;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; HUMAN; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; RHABDOMYOLYSIS; STEATOSIS; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS;

EID: 0037339344     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.3.325     Document Type: Review

References (101)

1. WOOD D, DE BACKER G, FAERGEMAN O, GRAHAM I, MANCIA G, PYÖRÄLÄ K: Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. (1998) 19:1434-1503.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 16:2486-2497.
3. MARON DJ, FAZIO S, MACRAE FL: Current perspectives on statins. Circulation (2000) 101:207-213.
4. Euroaspire II Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from Euroaspire II. Eur. Heart J. (2001) 22:554-572.
5. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
6. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West Of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333:1301-1307.
7. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. (1996) 335:1001-1009.
8. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA (1998) 279:1615-1622.
9. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339:1349-1357.
10. KNOPP RH: Drug treatment of lipid disorders. N. Engl. J. Med. (1999) 341:498-511.
11. LIAO JK: Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. (2002) 86:5-18.
12. FURBERG CD, PITT B: Withdrawal of cerivastatin from the world market. Curr. Control. Trials Cardiovasc. Med. (2001) 2:205-207.
13. SICA DA, GEHR TWB: Rhabdomyolysis and statin therapy: relevance to the elderly. Am. J. Geriatr. Cardiol. (2002) 11:48-55.
14. HAMELIN BA, TURGEON J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. (1998) 19:26-37.
15. MCTAGGART F, BUCKETT L, DAVIDSON R et al.: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. (2001) 87(Suppl.):28B-32B.
16. SCHACHTER M: Statins, drugs interactions and cytochrome P450. Br. J. Cardiol. (2001) 8:311-317.
17. OLSSON AG, MCTAGGART F, RAZA A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. (2002) 20:303-328.
18. BARTER P, SHEPHERD J, BROWN WV, BAYS H, SOUTHWORTH H, STRUTT K: Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):142.
19. HAMILTON-CRAIG I, SCHAEFER E, FARNIER M, KOREN M, SOUTHWORTH H, PEARS J: Rosuvastatin produces significantly greater reductions in low-density lipoprotein cholesterol and more patients achieve treatment goals compared with simvastatin. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):146.
20. WIKLUND O, DAVIDSON M, CHITRA R, HUTCHINSON H, RAZA A: Rosuvastatin is more effective than atorvastatin in modifying lipid profiles and achieving National Cholesterol Education Program Adult Treatment Panel III LDL-cholesterol goals. Atherosclerosis (2002) 3(Suppl.):237.
21. STEIN E, STRUTT KL, MILLER E, SOUTHWORTH H: ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. (2001) 37(Suppl. A):292A.
22. MARAIS D, RAAL F, STEIN E, RADER D, SMITH K, BLASETTO J: Effect of rosuvastatin on LDL-cholesterol, mevalonic acid and other lipid measurements in patients with homozygous familial hypercholesterolaemia. Atherosclerosis (2002) 3(Suppl.):159.
23. SHEPHERD J, HUNNINGHAKE D, HARRIS S, HUTCHINSON H, PEARS J: A review of the safety profile of rosuvastatin in an international Phase II/III clinical trial. Int. J. Clin. Pract. (2002) (Suppl. 124):15.
24. KAJINAMI K, KOIZUMI J, UEDA K, MIYAMOTO S, TAKEGOSHI T, MABUCHI H: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. The Hokuriku NK-104 Study Group. Am. J. Cardiol. (2000) 85:178-183.
25. SAITO Y, YAMADA N, TERAMOTO T et al.: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162:373-379.
26. SAITO Y, GOTO Y: Efficacy and safety of NK-104 (itavastatin) in hyperlipidemic subjects: a double-blind comparative study. Atherosclerosis (2000) 151:154.
27. INSULL W, KOREN M, DAVIGNON J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137-144.
28. DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation (2002) 105:2159-2165.
29. DAVIDSON MH, DILLON MA, GORDON B et al.: Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159:1893-1900.
30. KNOPP RH, GITTER H, TRUITT T et al.: Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomised, double-blind, placebo-controlled trial. Atherosclerosis (2001) 2(Suppl.):38.
31. KASHYAP ML, EVANS R, SIMMONS PD, KOHLER RM, MCGOVERN ME: New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J. Am. Coll. Cardiol. (2000) 35(Suppl. A):326.
32. DAVIDSON MH, TOTH P, WEISS S et al.: Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol. (2001) 24:467-474.
33. SONE H, TAKAHASHI A, SHIMANO H et al.: HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. (2002) 71:2403-2412.
34. KAJINAMI K, MABUCHI H, SAITO Y: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs (2000) 9:2653-2661.
35. KNOPP RH: Drug treatment of lipid disorders. N. Engl. J. Med. (1999) 341:498-511.
36. Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA (1975) 231:360-381.
37. BROWN G, ALBERS JJ, FISHER LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with men with high levels of apolipoprotein B. N. Engl. J. Med. (1990) 323:1289-1298.
38. KNOPP RH: Evaluating niacin in its various forms. Am. J. Cardiol. (2000) 86(Suppl. 1):51-56.
39. GARG A, GRUNDY SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA (1990) 264:723-726.
40. CAPUZZI DM, GUYTON JR, MORGAN JM et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol. (1998) 82:74U-81U.
41. GOLDBERG A, ALAGONA P Jr, CAPUZZI DM et al.: Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J. Cardiol. (2000) 85:1100-1105.
42. KNOPP RH, ALAGONA P, DAVIDSON M et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism (1998) 47:1097-1104.
43. BAYS H: Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am. J. Cardiol. (2002) 90(Suppl.):30K-43K.
44. WOLFE ML, VARTANIAN SF, ROSS JL et al.: Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am. J. Cardiol. (2001) 87:476-479.
45. BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345:1583-1592.
46. HIYOSHI H, YANAGIMACHI M, ITO M et al.: Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. J. Lipid Res. (2000) 41:1136-1144.
47. HIYOSHI H, YANAGIMACHI M, ITO M et al.: Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur. J. Pharmacol. (2001) 431:345-352.
48. UGAWA T, KAKUTA H, MORITANI H, INAGAKI O: Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. Br. J. Pharmacol. (2002) 137:561-569.
49. WATANABE S, HIRAI H, ISHIGURO M et al.: CJ-15,183, a new inhibitor of squalene synthase produced by a fungus, Aspergillus aculeatus. J. Antibiot. (Tokyo) (2001) 54:904-910.
50. JAMIL H, GORDON DA, EUSTICE DC et al.: An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc. Natl. Acad. Sci. USA (1996) 93:11991-11995.
51. ROBL JA, SULSKY R, SUN CQ et al.: A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem. (2001) 44:851-856.
52. HIATT JG, SHAMSIE SG, SCHECTMAN G: Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am. J. Managed Care (1999) 5:437-444.
53. STEINMETZ KL: Colesevelam hydrochloride. Am. J. Health Syst. Pharm. (2002) 59:932-939.
54. DAVIDSON MH, DICKLIN MR, MAKI KC, KLEINPELL RM: Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol lowering agent. Expert Opin. Investig. Drugs (2000) 9:2663-2671.
55. KNAPP HH, SCHROTT H, MA P et al.: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352-360.
56. HARA S, HIGAKI J, HIGASHINO K et al.: S-8921, an ileal Na+/bile acid cotransporter inhibitor decreases serum cholesterol in hamsters. Life Sci. (1997) 60:365-370.
57. ICHIHASHI T, IZAWA M, MIYATA K, MIZUI T, HIRANO K, TAKAGISHI Y: Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J. Pharmacol. Exp. Ther. (1998) 284:43-50.
58. HIGAKI J, HARA S, TAKASU N et al.: Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1304-1311.
59. KESANIEMI YA, MIETTINEN TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur. J. Clin. Invest. (1987) 17:391-395.
60. LAW M: Plant sterol and stanol margarines and health. Br. Med. J. (2001) 320:861-864.
61. NIGON F, SERFATY-LACRONIÈRE C, BEUCLER I et al.: Plant sterol-enriched margarine lowers plasma LDL-C in hyperlipidemic subjects with low cholesterol intake: effects of fibrate treatment. Clin. Chem. Lab. Med. (2001) 39:634-640.
62. DETMERS PA, PATEL S, HERNANDEZ M et al.: A target for cholesterol absorption inhibitors in the enterocyte brush border membrane. Biochim. Biophys. Acta (2000) 20:243-252.
63. DUJOVNE CA, ETTINGER MP, MCNEER JF et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. (2002) 90:1092-1097.
64. DAVIDSON M, MCGARRY T, BETTIS R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 40:2125-2134.
65. LIPKA L, KERZNER B, CORBELLI J et al.: Results of ezetimibe co-adminstered with lovastatin in 548 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):430B.
66. MELANI L, MILLS R, HASSMAN D et al.: Ezetimibe co-adminstered with pravastatin in 538 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):135B.
67. BALLANTYNE C, HOURI J, NOTARBARTOLO A et al.: Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. The Ezetimibe Study Group. J. Am. Coll. Cardiol. (2002) 39(Suppl. A):227A.
68. GAGNE C, BAYS HE, WEISS SR et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with hypercholesterolemia. Am. J. Cardiol. (2002) 90:1084-1091.
69. GAGNE C, GAUDET D, BRUCKERT E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469-2475.
70. GRAND-PERRET T, BOUILLOT A, PERROT A, COMMANS S, WALKER M, ISSANDOU M: SCAP ligands are potent new lipid-lowering drugs. Nat. Med. (2001) 7:1332-1338.
71. BOCAN TMA, KRAUSE BR, ROSEBURY WS et al.: The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. (2000) 20:70-79.
72. AZUMA Y, KAWASAKI T, IKEMOTO K et al.: Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits. Jpn. J. Pharmacol. (1998) 78:355-364.
73. JUNQUERO D, BRUNIQUEL F, N'GUYEN X et al.: F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. Atherosclerosis (2001) 155:131-142.
74. SACKS FM: The role of HDL cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. The Expert Group On HDL Cholesterol. Am. J. Cardiol. (2002) 90:139-143.
75. RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. (1999) 341:410-418.
76. FRANCESCHINI G, VECCHIO G, GIANFRANCESCHI G, MAGANI D, SIRTORI CR: Apolipoprotein A-I Milano: accelerated binding and dissociation from lipids of a human apolipoprotein variant. J. Biol. Chem. (1985) 260:16321-16325.
77. BRUCKERT E, VON ECKARDSTEIN A, FUNKE H et al.: The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I Milano. Atherosclerosis (1997) 128:121-128.
78. BANKA CL: High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. (1996) 7:139-142.
79. BERLINER JA, HEINECKE JW: The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. (1996) 20:707-727.
80. BARTER PJ, RYE KA: High density lipoproteins and coronary heart disease. Atherosclerosis (1996) 121:1-12.
81. SHAH PK, NILSSON J, KAUL S et al.: Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation (1998) 97:780-785.
82. TALL AR: Plasma lipid transfer proteins. Ann. Rev. Biochem. (1995) 64:235-257.
83. RONG JX, FISHER EA: High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis. Ann. Med. (2000) 32:642-651.
84. INAZU A, BROWN ML, HESLER CB et al.: Increased high-density lipoprotein levels caused by a common cholesteryl ester transfer protein gene mutation. N. Engl. J. Med. (1990) 323:1234-1238.
85. BRUCE C, SHARP DS, TALL AR: Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J. Lipid Res. (1998) 39:1071-1078.
86. PLUMP AS, MASUCCI-MAGOULAS L, BRUCE C, BISGAIER CL, BRESLOW JL, TALL AR: Increased atherosclerosis in ApoE and LDL receptor knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1105-1110.
87. SHINKAI H, MAEDA K, YAMASAKI T, OKAMOTO H, UCHIDA I: bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J. Med. Chem. (2000) 43:3566-3572.
88. OKAMOTO H, YONEMORI F, WAKITANI K, MINOWA T, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203-207.
89. GODSLAND IF: Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. (2001) 75:898-915.
90. HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. The Heart and Estrogen/Progestin Replacement (HERS) Study Group. JAMA (1998) 280:605-613.
91. ALEXANDERSEN P, RIIS BJ, STAKKESTAD JA, DELMAS PD, CHRISTIANSEN C: Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J. Clin. Endocrinol. Metab. (2001) 86:755-760.
92. SANDERS TA, DEAN TS, GRAINGER D, MILLER GI, WISEMAN H: Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am. J. Clin. Nutr. (2002) 76:373-377.
93. CLIFTON-BLIGH PB, BABER RJ, FULCHER GR, NERY ML, MORETON T: The effect of isoflavones extracted from red clover (Romostil) on lipid metabolism. Menopause (2001) 8:259-265.
94. CLAUDEL T, LEIBOWITZ MD, FIEVET C et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA (2001) 98:2610-2615.
95. MUKHERJEE R, STRASSER J, JOW L, HOENER P, PATERNITI JR Jr, HEYMAN RA: RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioseler. Thromb. Vasc. Biol. (1998) 18:272-276.
96. RIMM EB, STAMPFER MJ, ASCHERIO A, GIOVANNUCCI E, COLDITZ GA, WILLETT WC: Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. (1993) 328:1450-1456.
97. STAMPFER MJ, HENNECKENS CH, MANSON JE, COLDITZ GA, ROSNER B, WILLETT WC: Vitamin E consumption and the risk of coronary heart disease in women. N. Engl. J. Med. (1993) 328:1444-1449.
98. KRITHARIDES L, STOCKER R. The use of antioxidant Suppl.s in coronary heart diseases. Atherosclerosis (2002) 164:211-219.
99. ZUCKERMAN SH, KAUFFMAN RF, EVANS GF: Peroxisome proliferator-activated receptor alpha, gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids (2002) 37:487-494.
100. WAYMAN NS, HATTORIY, MCDONALD MC et al.: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. (2002) 16:1027-1040.
101. LJUNG B, BAMBERG K, DAHLLOF B et al.: AZ 242, a novel PPAR alpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. (2002) 43:1855-1863.